Health Science Journal

  • ISSN: 1108-7366
  • Journal h-index: 61
  • Journal CiteScore: 17.30
  • Journal Impact Factor: 18.23
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Moschowitz Syndrome: Case Report

XX Congresso Regionale FADOI CAMPANIA: Non ci siamo mai fermati
Italy 2021

Casaburi C, Serpico R, Dorato M and Ranucci RAN

U.O.C. Internal Medicine, P.O.â�?S.Maria delle Grazieâ�?, Pozzuoli (NA), Italy

Posters & Accepted Abstracts: Health Sci J


Background: Moschowitz syndrome is an acute syndrome characterized by purpura, hemolytic anemia and thrombocytopenia. The incidence is 0,4/100000/year. In contrast of hemolytic-uremic syndrome, it shows neurological disease in 90% of the cases, and not always renal insufficiency. This syndrome is characterized by ADAMTS13 protein deficiency; so the ultralarge multimeter of the von-Willebrand factor, secreted by activated endothelial cells, is not appropriately cleaved between Tyr1605-Met1606, causing spontaneous and massive platelet aggregation in many organs, exept lung. It’s caused by a genetic mutation of 9q34 gene or it’s acquired for immune mediated mechanisms. Case history: A 47 years old male presented anaemia (Hb: 6,6 g/ dL), PLT 5000, headache, fever, confusion and petechiae. Blood workup showed total bilirubin 4,2 mg/dL, with indirect bilirubin 2,9 mg/dL, increased levels of LDH and ferritin, haptoglobin 8 mg/ dL. ADAMTS13 activity assays depicted reduction of its activity (0,2%) with inhibitory levels (9,28 BU/mL). In three days diagnosis was made. Discussion: The differential diagnosis includes SEU, CID, HELLP syndrome, HIT. The therapy is plasmapheresis; in refractory PTT Rituximab, an anti CD20 monoclonal antibody, and Caplacizumab, an inhibitor of interaction between von Willebrand factor and platelets. It’s necessary an early diagnosis for its poor prognosis.